Comparison
Citicoline vs Hexarelin
Side-by-side of Citicoline and Hexarelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
Hexarelin
Hexarelin peptide is a ghrelin-receptor hexapeptide. Largest acute GH pulse in the GHRP class, highest cortisol and prolactin lift, CD36 cardioprotective sign.
Effects at a glance
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
Hexarelin
- •Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
- •Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
- •Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
- •More cortisol and prolactin elevation than GHRP-2 or ipamorelin
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
- •Banned by WADA under S2; advanced through phase 2 trials but never reached registration
Side-by-side
| Attribute | Citicoline | Hexarelin |
|---|---|---|
| Category | supplement | peptide |
| Also known as | CDP-choline, cytidine 5'-diphosphocholine, Cognizin | Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Half-life (hr) ↗ | 56 | 1 |
| Typical dose (mg) ↗ | 500 | 0.1 |
| Dosing frequency | 1 to 2 times daily | 1-2x daily |
| Routes | oral, intravenous | subcutaneous, intranasal, intravenous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 2 | 0.5 |
| Molecular weight | 488.32 | 887.04 |
| Molecular formula | C14H26N4O11P2 | C47H58N12O6 |
| Mechanism | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. | Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. |
| Legal status | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world | Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement (US); Rx in most of the world | Not scheduled (research chemical) |
| Pregnancy | Insufficient data for routine use | Insufficient data; not recommended |
| CAS | 987-78-0 | 140703-51-1 |
| PubChem CID | 13804 | 3037387 |
| Wikidata | Q411470 | Q5743550 |
Safety profile
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
Hexarelin
Common side effects
- water retention
- vivid dreams
- head pressure or flushing
- transient lethargy
- tingling at injection site
- moderate hunger
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin-sensitive states
Interactions
- CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: amplify cortisol load; blunt GH response(moderate)
Which Should You Take?
Citicoline comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Citicoline.
- → If your priority is stroke recovery, pick Citicoline.
- → If your priority is growth-hormone axis, pick Hexarelin.
- → If your priority is post-training recovery, pick Hexarelin.
Edge case: If you want to avoid research-only / gray-market sourcing, Citicoline is the more accessible choice.
Default choice: Citicoline. Lower friction to source, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Citicoline and Hexarelin?
Citicoline and Hexarelin differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Citicoline or Hexarelin?
Citicoline half-life is 56 hours; Hexarelin half-life is 1 hours.
Can you stack Citicoline with Hexarelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper